Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Clemastine Fumarate
Clemastine · 1 trial · 7 indications
The efficacy of clemastine relative to placebo at increasing the myelin water fraction (MWF) (measured in %) from magnetic resonance imaging of the corpus callosum.
The efficacy of clemastine relative to placebo at increasing the myelin water fraction (MWF) (measured in %) from magnetic resonance imaging of the corpus callosum. Change = (3-month % - Baseline %)
The efficacy of clemastine relative to placebo at increasing the myelin water fraction (MWF) (measured in %) from magnetic resonance imaging of the corpus callosum. Change = (6-month % - Baseline %)
The efficacy of clemastine relative to placebo at shortening the T1 relaxation time (measured in seconds) within the corpus callosum using T1 mapping protocols in an MRI.
The efficacy of clemastine relative to placebo at shortening the T1 relaxation time (measured in seconds) within the corpus callosum using T1 mapping protocols in an MRI. Change = (3-month time - Baseline time)
The efficacy of clemastine relative to placebo at shortening the T1 relaxation time (measured in seconds) within the corpus callosum using T1 mapping protocols in an MRI. Change = (6-month time - Baseline time)
The efficacy of clemastine relative to placebo at increasing the ultrashort echo time (UTE) fraction (measured in %) derived from magnetic resonance imaging of the corpus callosum.
The efficacy of clemastine relative to placebo at increasing the ultrashort echo time (UTE) fraction (measured in %) derived from magnetic resonance imaging of the corpus callosum. Change = (3-month % - Baseline %)
The efficacy of clemastine relative to placebo at increasing the ultrashort echo time (UTE) fraction (measured in %) derived from magnetic resonance imaging of the corpus callosum. Change = (6-month % - Baseline %)
| Arm | Type | Description |
|---|---|---|
| Clemastine 8 mg, then Placebo | EXPERIMENTAL | Group 1 will receive the treatment (clemastine 8mg/day) for the first 90 days and then switch to the placebo (a sugar pill) for the remaining 90 days |
| Placebo, then Clemastine 8 mg | EXPERIMENTAL | Group 2 will receive the placebo (a sugar pill) for the first 90 days and then switch to the treatment (clemastine 8mg/day) for the remaining 90 days |
| Name | Type | Description |
|---|---|---|
| Clemastine Fumarate | DRUG | 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy |
| Placebo | DRUG | Matched sugar tablet |
Inclusion Criteria: * Written informed consent must be obtained prior to any assessment being performed. * Patients diagnosed with relapsing remitting multiple sclerosis and a disease duration of \< 15 years * Male or female patients aged 18-55 years (inclusive) * Use of appropriate contraception d...
Clemastine is an investigational small molecule being studied for the treatment of Multiple Sclerosis (MS). It is currently in Phase 1 clinical development, with a focus on assessing its potential as a myelin repair therapy in MS patients.
Clemastine is a small molecule being investigated for its potential to promote myelin repair in Multiple Sclerosis. The specific molecular target of Clemastine in this context has not been disclosed in the available information.
Clemastine is being developed by United Therapeutics Corporation, a biopharmaceutical company listed on the NASDAQ under the ticker symbol UTHR.
Clemastine is currently in Phase 1 clinical development for Multiple Sclerosis. It is an investigational drug and has not yet been approved by regulatory authorities.
Clemastine is being evaluated in a Phase 1 clinical trial with the identifier NCT05359653. This randomized, double-blind, controlled study is assessing changes in multi-parametric MRI in MS patients taking Clemastine Fumarate as a myelin repair therapy.
Yes, Clemastine is also known as Clemastine Fumarate. The clinical trial NCT05359653 specifically evaluates Clemastine Fumarate as a myelin repair therapy in patients with Multiple Sclerosis.